<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211714</url>
  </required_header>
  <id_info>
    <org_study_id>EXG-US-01</org_study_id>
    <nct_id>NCT04211714</nct_id>
  </id_info>
  <brief_title>Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure</brief_title>
  <official_title>A Phase I/II Study to Evaluate the Safety and Tolerability of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixirgen Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elixirgen Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II, open label, single center study to assess the safety and tolerability&#xD;
      of EXG34217 in bone marrow failure patients with telomere biology disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, open label study in up to 12 subjects with telomere biology disorders&#xD;
      with bone marrow failure. The study is open to all participants regardless of gender or&#xD;
      ethnicity. Subjects who are enrolled but not evaluable will be replaced.&#xD;
&#xD;
      Subjects will sign a consent form prior to any study related procedure and will complete&#xD;
      baseline screening assessments. Subjects for this study will not require any preparative&#xD;
      regimen such as chemotherapy or radiation.&#xD;
&#xD;
      The study will be conducted in three parts&#xD;
&#xD;
        -  Peripheral blood mononuclear cells (PBMNCs) collection; mobilization and apheresis,&#xD;
&#xD;
        -  Ex vivo cell processing&#xD;
&#xD;
        -  Processed cell infusion and post-infusion safety monitoring,&#xD;
&#xD;
        -  Follow-up (Week 2, 3,4,5, Months 1, 2,3,4,5,6,9 and 12)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. Incidence and nature of adverse events, vital signs, weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a change in in physical examination</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>Physical examination changes General appearance ,Head, eyes, ears, nose, and throat, Respiratory, Cardiovascular, Musculoskeletal, Abdomen, Neurologic, Extremities, Dermatologic, Lymphatic)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a change in Electrocardiography (ECG)</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>ECG (standard digital 12-lead in singlicate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a change in clinical laboratory evaluations</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>Changes in clinical laboratory evaluations (Hematology, Blood chemistry, Coagulation, and Urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a change of Immunogenicity</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>Change in Antibody against virus vector and transgene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in telomere length</measure>
    <time_frame>Screening, Month1,3,6 and 12</time_frame>
    <description>Change in telomere length in any peripheral blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improvement of blood counts.</measure>
    <time_frame>Multiple times for the duration of the study (baseline through Month 12)</time_frame>
    <description>Blood counts: neutrophils,platelets, or hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Telomere Shortening</condition>
  <condition>Bone Marrow Failure</condition>
  <arm_group>
    <arm_group_label>EXG34217</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single autologous CD34+ cells contacted ex vivo with EXG-001</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EXG34217</intervention_name>
    <description>Single infusion</description>
    <arm_group_label>EXG34217</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Mild or moderate bone marrow failure defined by satisfying specific conditions.&#xD;
&#xD;
          -  Diagnosis of telomere biology disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential or breastfeeding.&#xD;
&#xD;
          -  Patients with cancer who are on active chemotherapeutic treatment.&#xD;
&#xD;
          -  Patients with severe bone marrow failure.&#xD;
&#xD;
          -  Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow&#xD;
             examination.&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infections.&#xD;
&#xD;
          -  Prior allogeneic marrow or stem cell transplantation.&#xD;
&#xD;
          -  Patients who are not eligible for G-CSF and plerixafor dosing.&#xD;
&#xD;
          -  Patients who are not eligible for the apheresis.&#xD;
&#xD;
          -  Patients currently taking or have taken danazol and androgens within 60 days prior to&#xD;
             Day 1.&#xD;
&#xD;
          -  Patients with any other clinically relevant acute or chronic diseases which could&#xD;
             interfere with the patients' safety during the trial, expose them to undue risk, or&#xD;
             which could interfere with study objectives.&#xD;
&#xD;
          -  Patients who have participated in another clinical trial with an investigational drug&#xD;
             within the previous 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasiani Myers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children Hospital Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martine Francis</last_name>
    <phone>301-343-8894</phone>
    <email>martine@mafinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minako Koga</last_name>
    <phone>202-615-6004</phone>
    <email>mkoga@kmphc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasiani Myers, MD</last_name>
      <phone>513-803-3218</phone>
      <email>Kasiani.Myers@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Monica Trapp</last_name>
      <phone>(513) 803-3218</phone>
      <email>Monica.Trapp@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kasani Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

